| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/25/2009 | CN101371820A Anticancer sustained-release agent containing methotrexate potentiating agent |
| 02/25/2009 | CN101371710A Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof |
| 02/25/2009 | CN100463704C Integrated medicament conveying system |
| 02/25/2009 | CN100463668C Reversibly hot gelified water soluble medicine composition |
| 02/24/2009 | US7495086 TWEAK receptor |
| 02/24/2009 | US7495020 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 02/24/2009 | US7495019 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use |
| 02/24/2009 | US7494988 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| 02/24/2009 | US7494981 Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors |
| 02/24/2009 | US7494977 Polypeptides homologous to VEGF and BMP1 |
| 02/24/2009 | US7494976 Antiinflammatory agents; anticancer agents; cholesterol binding protein |
| 02/24/2009 | US7494975 A polyanion selected from a heparin, a dextran, a pentosan, resobene, curdian sulfate, or 2-naphthalene sulfonate polymer and a CD4 polypeptide with a beta-hairpin confirmation; blocking HIV interaction with coreceptors |
| 02/24/2009 | US7494824 Interactive system for presenting and eliminating substances |
| 02/24/2009 | US7494808 Methods and interferon deficient substrates for the propagation of viruses |
| 02/24/2009 | US7494768 Mutational profiles in HIV-1 protease and reverse transcriptase correlated with phenotypic drug resistance |
| 02/24/2009 | US7494666 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells |
| 02/24/2009 | US7494654 Compositions and methods for treating cardiovascular conditions with botulinum toxin |
| 02/24/2009 | CA2469813C Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 02/24/2009 | CA2444208C Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
| 02/24/2009 | CA2418613C Spray device |
| 02/24/2009 | CA2415364C Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/24/2009 | CA2339913C Pharmaceutical formulations and method for making |
| 02/19/2009 | WO2009023845A2 Combination therapy with synthetic triterpenoids and gemcitabine |
| 02/19/2009 | WO2009023471A2 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation |
| 02/19/2009 | WO2009023411A1 Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| 02/19/2009 | WO2009022897A2 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 02/19/2009 | WO2009022687A1 Phenylacetic acid compound |
| 02/19/2009 | WO2009022399A1 Novel microorganism having gastric juice promoting action and composition secreted by the same |
| 02/19/2009 | WO2009022179A2 Glucokinase activators in the treatment of osteoarthritis |
| 02/19/2009 | WO2009022096A1 Drug combinations for the treatment of sialorrhoea |
| 02/19/2009 | WO2009022010A1 Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor |
| 02/19/2009 | WO2009021322A1 Tumor cell-derived microvesicles |
| 02/19/2009 | WO2009006141A3 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 02/19/2009 | WO2009001040A3 Treatment of depression |
| 02/19/2009 | WO2008060766A3 Histamine h4 receptor ligands for use in pain treatment |
| 02/19/2009 | WO2008033754A3 Xanthine derivatives in methods and compositions for the treatment of vascular depression |
| 02/19/2009 | US20090049561 Non-human animal exhibiting bone metastasis of tumor cells |
| 02/19/2009 | US20090048659 Medical devices having sol-gel derived ceramic regions with molded submicron surface features |
| 02/19/2009 | US20090048350 Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method |
| 02/19/2009 | US20090048287 Compositions useful for treating gastrointestinal motility disorders |
| 02/19/2009 | US20090048173 Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors |
| 02/19/2009 | US20090048154 Compositions and Methods for Treating Diabetes |
| 02/19/2009 | US20090047741 Compositions and methods comprising a ligand of chemerin R |
| 02/19/2009 | US20090047687 Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation |
| 02/19/2009 | US20090047307 Chemo-Immunotherapy Method |
| 02/19/2009 | US20090047306 Adjuvant compositions |
| 02/19/2009 | US20090047292 Graft rejection suppressors |
| 02/19/2009 | US20090047239 Stabilised IL-21 Compositions |
| 02/19/2009 | US20090047217 Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby |
| 02/19/2009 | CA2736382A1 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 02/19/2009 | CA2733672A1 Tumor cell-derived microvesicles |
| 02/19/2009 | CA2696271A1 Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor |
| 02/19/2009 | CA2695757A1 Phenylacetic acid compound |
| 02/19/2009 | CA2684873A1 Anti-bacterial drug targeting of genome maintenance interfaces |
| 02/18/2009 | EP2026073A1 Diagnostics and therapeutics for macular degeneration-related disorders |
| 02/18/2009 | EP2025347A1 Prophylactic and therapeutic agent for cancer |
| 02/18/2009 | EP2025346A1 Muscle regeneration promoter |
| 02/18/2009 | EP2023956A2 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor |
| 02/18/2009 | EP2023923A2 Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
| 02/18/2009 | EP2023921A1 Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm |
| 02/18/2009 | EP2023918A2 Method for the treatment and prevention of ocular disorders |
| 02/18/2009 | EP1539727B1 Compounds, compositions, and methods for treating cellular proliferative diseases |
| 02/18/2009 | EP1513519B1 The use of substituted cyanopyrrolidines for treating hyperlipidemia |
| 02/18/2009 | EP1513493B1 Analgesics |
| 02/18/2009 | EP1448281B1 Therapeutic coating for an intravascular implant |
| 02/18/2009 | EP1135467B1 Psca: prostate stem cell antigen and uses thereof |
| 02/18/2009 | EP1071955B2 Improved immunodiagnostic assays using reducing agents |
| 02/18/2009 | EP0812184B2 Nitric oxide synthase inhibitors for topical use |
| 02/18/2009 | CN101370555A Novel use of (-)-epigallocatechin gallate |
| 02/18/2009 | CN101370522A Specific therapy using integrin ligands for treating cancer |
| 02/18/2009 | CN101370521A Remedy for disease associated with choroidal angiogenesis |
| 02/18/2009 | CN101370520A Pharmaceutical composition for prevention or treatment of cardiac failure |
| 02/18/2009 | CN101370503A Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts |
| 02/18/2009 | CN101370499A Combination of ACHE inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction |
| 02/18/2009 | CN101370489A Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases |
| 02/18/2009 | CN101366699A Novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
| 02/18/2009 | CN100462080C Enteral composition for the prevention and/or treatment of sepsis |
| 02/18/2009 | CN100462073C Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 02/17/2009 | US7491801 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 02/17/2009 | US7491796 Retro-inversion peptides that target GIT receptors and related methods |
| 02/17/2009 | US7491746 Treating cell proliferation disorder, anticancer agents |
| 02/17/2009 | US7491730 Compositions useful as inhibitors of GSK-3 |
| 02/17/2009 | US7491721 N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide; tuberculosis including multi-drug resistant and/or latent tuberculosis; antitubercular drugs |
| 02/17/2009 | US7491693 Administering High Density Lipoproteins |
| 02/17/2009 | US7491550 Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) |
| 02/17/2009 | US7491406 Fast dissolving orally consumable films |
| 02/17/2009 | US7491395 Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| 02/17/2009 | US7491389 Bone marrow; controlling cell differentiation |
| 02/17/2009 | US7491388 human fibroblasts are contacted with allogeneic T lymphocytes, in vitro, fibroblasts suppressed an ongoing mixed lymphocyte reaction co-culturing cells from different individuals results in a T cell response, manifested by activation and proliferation of the T cells |
| 02/17/2009 | US7491384 administering enothelial growth factors with delivery vehicle (powdered bone, tricalcium phosphate, hydroxyapatite, polymethacrylate, biodegradable polyester, aqueous polymeric gel, or fibrin sealant) |
| 02/17/2009 | US7491047 Delivery of antihistamines through an inhalation route |
| 02/17/2009 | CA2383785C Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 02/17/2009 | CA2383555C 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/17/2009 | CA2356087C Methods and compositions for treatment of cell proliferative disorders |
| 02/17/2009 | CA2217054C Compositions and methods for inhibiting thrombogenesis |
| 02/12/2009 | WO2009020844A1 Use of interleukin-22 in the treatment of fatty liver disease |
| 02/12/2009 | WO2009020561A2 Compositions and methods of use thereof, for the treatment of oral pain, comprising cloves or extract thereof in combination with a steroid |
| 02/12/2009 | WO2009020534A2 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| 02/12/2009 | WO2009020419A1 New treatment for chemical substance addiction |
| 02/12/2009 | WO2009020119A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |